3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
3
Sarcoma
1
Platinum-Resistant Lung Small Cell Carcinoma
1
Neoplasms
1
Leiomyosarcoma
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
PM 01183
×
Clear all
NCT06088290
2026-05-15
SaLuDo
PharmaMar
Phase 3
Active not recruiting
455 enrolled